多发性骨髓瘤导致肾损害的发病机制及诱发因素
The Pathogenesis and Predisposing Factors of Kidney Damage Caused by Multiple Myeloma
DOI: 10.12677/ACM.2023.133567, PDF,   
作者: 帕提古丽·买买提, 李素华*：新疆医科大学第一附属医院肾脏疾病中心，新疆 乌鲁木齐
关键词: 多发性骨髓瘤；肾损害；轻链；淀粉样变性；Multiple Myeloma； Renal Impairment； Light Chain； Amyloidosis
摘要: 肾脏损伤是多发性骨髓瘤最常见的并发症之一，是多发性骨髓瘤患者预后不良的因素之一，可作为多发性骨髓瘤的首发临床表现，已有相关研究证明肾损伤是导致多发性骨髓瘤患者死亡的独立危险因素，即使在新型抗肿瘤药物引入后多发性骨髓瘤合并肾脏损伤的患者总生存期较前得以改善，但较无肾损害的多发性骨髓瘤患者仍较差。本综述就多发性骨髓瘤导致肾损害的危险因素、发病机制及诱发因素展开论述，为临床早期预防多发性骨髓瘤相关肾损害、改善多发性骨髓瘤患者肾功能以及多发性骨髓瘤整体预后提供指导价值。
Abstract: Kidney injury is one of the most common complications of multiple myeloma, one of the poor prognosis factors in patients with multiple myeloma, and can be the first clinical manifestation of multiple myeloma. Relevant studies have proved that kidney injury is an independent risk factor for death in patients with multiple myeloma, even though the overall survival of patients with multiple myeloma complicated with kidney injury is improved after the introduction of new anti-tumor drugs, but it was still worse than patients without renal damage. This review discussed the risk factors, pathogenesis and inducement factors of multiple myeloma-induced renal impairment, providing guidance value for early clinical prevention of multiple myeloma-related renal impair-ment, improvement of renal function in patients with multiple myeloma and overall prognosis of multiple myeloma.
文章引用：帕提古丽·买买提, 李素华. 多发性骨髓瘤导致肾损害的发病机制及诱发因素[J]. 临床医学进展, 2023, 13(3): 3953-3957. https://doi.org/10.12677/ACM.2023.133567

参考文献

[1] Cullis, J. (2019) Haematology: Multiple Myeloma. Clinical Medicine, 19, 188-188. [Google Scholar] [CrossRef] [PubMed]
[2] Pawlyn, C. and Davies, F.E. (2019) Toward Personalized Treatment in Multiple Myeloma Based on Molecular Characteristics. Blood, 133, 660-675. [Google Scholar] [CrossRef] [PubMed]
[3] Mene, P., Giammarioli, E., Fofi, C., et al. (2018) Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: A Case Series. Kidney & Blood Pressure Research, 43, 1263-1272. [Google Scholar] [CrossRef] [PubMed]
[4] Bozic, B., Rutner, J., Zheng, C., et al. (2021) Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. Cancers, 13, 5036. [Google Scholar] [CrossRef] [PubMed]
[5] Knudsen, L.M., Hjorth, M. and Hippe, E. (2000) Renal Failure in Multiple Myeloma: Reversibility and Impact on the Prognosis. Nordic Myeloma Study Group. European Journal of Haematology, 65, 175-181. [Google Scholar] [CrossRef] [PubMed]
[6] Hsu, P., Lin, T.-W., Gau, J.-P., et al. (2015) Risk of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma. Medicine, 94, e2305. [Google Scholar] [CrossRef] 
[7] Yan, G., Li, H.M., Zhang, Y.D., et al. (2022) Renal Insuffi-ciency Predicts Worse Prognosis in Newly Diagnosed IgD Multiple Myeloma Patients. Frontiers in Oncology, 12, Ar-ticle ID: 1012889. [Google Scholar] [CrossRef] [PubMed]
[8] Stompor, T., Zablocki, M. and Pankrac, K. (2012) Renal In-volvement in Multiple Myeloma. Polish Archives of Internal Medicine, 122, 443-448. [Google Scholar] [CrossRef] 
[9] Mene, P., Stoppacciaro, A., Lai, S., et al. (2022) Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges. International Journal of Neph-rology and Renovascular Disease, 15, 173-183. [Google Scholar] [CrossRef] 
[10] Kundu, S., Jha, S.B., Rivera, A.P., et al. (2022) Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Cureus, 14, e22585. [Google Scholar] [CrossRef] [PubMed]
[11] Karam, S. and Leung, N. (2020) Renal Involvement in Systemic Amy-loidosis Caused by Monoclonal Immunoglobulins. Hematology-Oncology Clinics of North America, 34, 1069. [Google Scholar] [CrossRef] [PubMed]
[12] Lomas, O.C., Mouhieddine, T.H., Tahri, S., et al. (2020) Mono-clonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers (Basel), 12, 1554. [Google Scholar] [CrossRef] [PubMed]
[13] Yaday, P., Cockwell, P., Cook, M., et al. (2018) Serum Free Light Chain Levels and Renal Function at Diagnosis in Patients with Multiple Myeloma. BMC Nephrology, 19, Article No. 178. [Google Scholar] [CrossRef] [PubMed]
[14] Xu, J., Wang, M., Shen, Y., et al. (2021) Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study. Cancer Management and Research, 13, 1343-1356. [Google Scholar] [CrossRef] 
[15] Kaneko, S., Usui, J., Narimatsu, Y., et al. (2022) Renal Involvement of Monoclonal Immunoglobulin Deposition Disease Associated with an Unusual Monoclonal Immunoglobulin A Glycan Profile (vol. 14, pg 389, 2010). Clinical and Experimental Nephrology, 26, 733-733. [Google Scholar] [CrossRef] [PubMed]
[16] Ying, W.Z. and Sanders, P.W. (2001) Mapping the Binding Domain of Immunoglobulin Light Chains for Tamm-Horsfall Protein. The American Journal of Pathology, 158, 1859-1866. [Google Scholar] [CrossRef] 
[17] Anandh, U., Patrick, A. and Sharma, A. (2019) Coexistent Amyloid Fibrils in a Patient with Combined Light Chain Deposition Disease and Light Chain Cast Nephropathy. Indian Journal of Nephrology, 29, 204-206. [Google Scholar] [CrossRef] 
[18] Morgan, G.J., Buxbaum, J.N. and Kelly, J.W. (2021) Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis. Hemato, 2, 645-659. [Google Scholar] [CrossRef] [PubMed]
[19] Sanders, P.W. (2012) Mechanisms of Light Chain Injury along the Tubular Nephron. Journal of the American Society of Nephrology, 23, 1777-1781. [Google Scholar] [CrossRef] 
[20] Cruz-Solbes, A.S. and Youker, K. (2017) Epithelial to Mesenchymal Transition (EMT) and Endothelial to Mesenchymal Transition (EndMT): Role and Implications in Kidney Fibrosis. In: Miller, R.K., Ed., Kidney Development and Disease, Springer, Berlin, 345-372. [Google Scholar] [CrossRef] [PubMed]
[21] Sengul, S., Zwizinski, C. and Batuman, V. (2003) Role of MAPK Pathways in Light Chain-Induced Cytokine Production in Human Proximal Tubule Cells. American Journal of Physiology. Renal Physiology, 284, F1245-F1254. [Google Scholar] [CrossRef] [PubMed]
[22] Sathick, I.J., Drosou, M.E. and Leung, N. (2019) Myeloma Light Chain Cast Nephropathy, a Review. Journal of Nephrology, 32, 189-198. [Google Scholar] [CrossRef] [PubMed]
[23] Auron, A. and Alon, U.S. (2018) Hypercalcemia: A Consultant’s Approach. Pediatric Nephrology, 33, 1475-1488. [Google Scholar] [CrossRef] [PubMed]
[24] Xu, L., Zhao, B., Sun, Y., et al. (2022) Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal In-sufficiency. Biomed Research International, 2022, Article ID: 5536199. [Google Scholar] [CrossRef] [PubMed]
[25] Owoyemi, I., Sethi, S. and Leung, N. (2021) Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case. Kidney Medicine, 3, 303-306. [Google Scholar] [CrossRef] [PubMed]
[26] Rana, R., Cockwell, P., Drayson, M., et al. (2020) Renal Outcome in Patients with Newly Diagnosed Multiple Myeloma: Results from the UK NCRI Myeloma XI Trial. Blood Advances, 4, 5836-5845. [Google Scholar] [CrossRef] [PubMed]
[27] Yadav, P., Cook, M. and Cockwell, P. (2016) Current Trends of Renal Impairment in Multiple Myeloma. Kidney Diseases, 1, 241-257. [Google Scholar] [CrossRef] [PubMed]
[28] 刘玲. 多发性骨髓瘤并发急性肾损伤诱因回归分析[J]. 中国现代医药杂志, 2010, 12(3): 92-94.

为你推荐